CoChat
Sign Up
Cited by 119Cancer Immunotherapy and BiomarkersCancer, Hypoxia, and MetabolismImmune cells in cancer

The DOI matches its Crossref record; 468 of the 468 references it cites were found in a registry or an index.

Hypoxia and the phenomenon of immune exclusion

Open access
Pietrobon, Violena, Marincola, Francesco M.·2021·Journal of Translational Medicine
DOI 10.1186/s12967-020-02667-4PMC PMC7788724
Open this paper in CoChat — free accountOpen PDF

Abstract

Over the last few years, cancer immunotherapy experienced tremendous developments and it is nowadays considered a promising strategy against many types of cancer. However, the exclusion of lymphocytes from the tumor nest is a common phenomenon that limits the efficiency of immunotherapy in solid tumors. Despite several mechanisms proposed during the years to explain the immune excluded phenotype, at present, there is no integrated understanding about the role played by different models of immune exclusion in human cancers. Hypoxia is a hallmark of most solid tumors and, being a multifaceted and complex condition, shapes in a unique way the tumor microenvironment, affecting gene transcription and chromatin remodeling. In this review, we speculate about an upstream role for hypoxia as a common biological determinant of immune exclusion in solid tumors. We also discuss the current state of ex vivo and in vivo imaging of hypoxic determinants in relation to T cell distribution that could mechanisms of immune exclusion and discover functional-morphological tumor features that could support clinical monitoring.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12967-020-02667-4

Cites

468 of 468 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Mechanisms of HIF-1α protein stabilization in hypoxia and degradation in normoxia. a Under normal oxygen tension, HIF-α subunits are expressed, hydroxylated by a family of oxygen dependent prolyl hydroxylases (PHDs), recognised by the von-Hippel Lindau tumor suppressor (pVHL) which leads to HIF-α poly-ubiquitination and subsequent degradation by the 26S proteasome. b Under hypoxic conditions HIF-α is no longer hydroxylated but it dimerizes with the constitutively expressed HIF-β, enters the nucleus and binds to HREs to upregulate transcription of a group of hypoxic responsive genes. c Extensive modifications in chromatin structure, both HIF dependent and independent, also promote gene silencing
Fig. 1 Mechanisms of HIF-1α protein stabilization in hypoxia and degradation in normoxia. a Under normal oxygen tension, HIF-α subunits are expressed, hydroxylated by a family of oxygen dependent prolyl hydroxylases (PHDs), recognised by the von-Hippel Lindau tumor suppressor (pVHL) which leads to HIF-α poly-ubiquitination and subsequent degradation by the 26S proteasome. b Under hypoxic conditions HIF-α is no longer hydroxylated but it dimerizes with the constitutively expressed HIF-β, enters the nucleus and binds to HREs to upregulate transcription of a group of hypoxic responsive genes. c Extensive modifications in chromatin structure, both HIF dependent and independent, also promote gene silencingCC BY · PubMed Central
Fig. 2 Hypoxia-induced mechanical barriers. Mechanical barriers represent a category of determinants of immune exclusion where a lack of interaction between T cells and cancer cells is due to physical impediments. Hypoxia induced-mechanical barriers include neoangiogenesis (vascular accessibility), ECM remodeling (stromal fibrosis, collagen remodelling and crosslinking), EMT and cancer cell coating
Fig. 2 Hypoxia-induced mechanical barriers. Mechanical barriers represent a category of determinants of immune exclusion where a lack of interaction between T cells and cancer cells is due to physical impediments. Hypoxia induced-mechanical barriers include neoangiogenesis (vascular accessibility), ECM remodeling (stromal fibrosis, collagen remodelling and crosslinking), EMT and cancer cell coatingCC BY · PubMed Central
Fig. 3 Hypoxia-induced functional barriers. Functional barriers represent a class of impediments in which T cells are in close proximity with cancer cells, but their activity is impaired. Hypoxia-driven functional barriers include metabolic barriers, secreted soluble factors, danger sensing pathways and/or cell-intrinsic signaling
Fig. 3 Hypoxia-induced functional barriers. Functional barriers represent a class of impediments in which T cells are in close proximity with cancer cells, but their activity is impaired. Hypoxia-driven functional barriers include metabolic barriers, secreted soluble factors, danger sensing pathways and/or cell-intrinsic signalingCC BY · PubMed Central
Fig. 4 Scheme of ex vivo and in vivo techniques to detect hypoxia and immune cells. a Ex-vivo techniques could be useful to create topographic maps of hypoxic-induced physical and functional barriers in immune excluded tumor areas, providing mechanistic highlights into the organization of immune exclusion determinants. Bioinformatic and spatial transcriptomics could investigate hypoxic transcriptional profiles in correlation with ICR or TIS. Immunohistochemistry of exogenous compounds or HIF-induced proteins coupled to digital pathology of immune cells could provide functional and morphological insights. b In-vivo techniques to detect gradients of hypoxia and immune infiltration may be useful to monitor immunotherapy efficiency in hypoxic tumors (clinical setting). To detect hypoxia and immune cells in patients, non-invasive methodologies are preferred
Fig. 4 Scheme of ex vivo and in vivo techniques to detect hypoxia and immune cells. a Ex-vivo techniques could be useful to create topographic maps of hypoxic-induced physical and functional barriers in immune excluded tumor areas, providing mechanistic highlights into the organization of immune exclusion determinants. Bioinformatic and spatial transcriptomics could investigate hypoxic transcriptional profiles in correlation with ICR or TIS. Immunohistochemistry of exogenous compounds or HIF-induced proteins coupled to digital pathology of immune cells could provide functional and morphological insights. b In-vivo techniques to detect gradients of hypoxia and immune infiltration may be useful to monitor immunotherapy efficiency in hypoxic tumors (clinical setting). To detect hypoxia and immune cells in patients, non-invasive methodologies are preferredCC BY · PubMed Central
Fig. 5 Spatial transcriptomics workflow including the downstream analysis. a Histological tumor sections are stained with hematoxylin and eosin-stained and imaged before permeabilization. b The sections are placed on glass slides containing RT-primers arrayed as spots that corresponded to tissues domains. The barcoded microarrays contain printed spots of RT-primers with unique barcode sequences. The RT-primers at each spot have a unique spatial ID barcode, which is sequenced along with the transcript to enable trace-back to a specific tissue domain. c Sequencing. d After sequencing the gene expression profiles and factor activity map are created
Fig. 5 Spatial transcriptomics workflow including the downstream analysis. a Histological tumor sections are stained with hematoxylin and eosin-stained and imaged before permeabilization. b The sections are placed on glass slides containing RT-primers arrayed as spots that corresponded to tissues domains. The barcoded microarrays contain printed spots of RT-primers with unique barcode sequences. The RT-primers at each spot have a unique spatial ID barcode, which is sequenced along with the transcript to enable trace-back to a specific tissue domain. c Sequencing. d After sequencing the gene expression profiles and factor activity map are createdCC BY · PubMed Central
Fig. 6 Examples of hypoxia imaging in glioma. Postsurgical assessment of residual tumor showing a 18F-FMISO gradient, hypoxic areas are found in the surgical margin of the tumor. b 18F-FDG staining, marker for the tissue uptake of glucose and C) preoperative MRI showing the tumor mass in the right posterior parieto-occipital lobe
Fig. 6 Examples of hypoxia imaging in glioma. Postsurgical assessment of residual tumor showing a 18F-FMISO gradient, hypoxic areas are found in the surgical margin of the tumor. b 18F-FDG staining, marker for the tissue uptake of glucose and C) preoperative MRI showing the tumor mass in the right posterior parieto-occipital lobeCC BY · PubMed Central
Fig. 7 Comparative study of BOLD and TOLD to assess tumor oxygenation. BOLD and TOLD-MRI measures of oxygen gradients overlaid on a high-resolution image of a small Dunning prostate R3327-AT1 tumor in conditions of hyperoxia, 100% O2 (O2), return to normal air (Air) and carbogen breathing, 95% O2 and 5% CO2 (CB). Changes in signal intensity is represented by %ΔSI. Response maps compare final images versus baseline. Each map shows substantial intratumoral heterogeneity and differences in the heatmap pattern within the same treatment, between BOLD and TOLD
Fig. 7 Comparative study of BOLD and TOLD to assess tumor oxygenation. BOLD and TOLD-MRI measures of oxygen gradients overlaid on a high-resolution image of a small Dunning prostate R3327-AT1 tumor in conditions of hyperoxia, 100% O2 (O2), return to normal air (Air) and carbogen breathing, 95% O2 and 5% CO2 (CB). Changes in signal intensity is represented by %ΔSI. Response maps compare final images versus baseline. Each map shows substantial intratumoral heterogeneity and differences in the heatmap pattern within the same treatment, between BOLD and TOLDCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

2 retracted

Items 201–400 of 468

Research works printed but not linked: 2

  1. Wang Z, et al. Transglutaminase-2 of pancreatic cancer cells assembles a CXCL12-keratin 19-coat that mediates the resistance to immunotherapy. bioRxiv, 2019;2:776419.
  2. Zhang Z, et al. PI3K/Akt and HIF1 signaling pathway in hypoxiaischemia (Review). Mol Med Rep. 2018;18(4):3547–54.

Cited by

Sorted by citations

See all 119

Related

See all

Metadata

Authors
Pietrobon, V., & Marincola, F. M.
Affiliations
Refuge Biotechnologies (United States) (US)
Corresponding author
Pietrobon, Violena
ORCID
Venue
Journal of Translational Medicine
Publisher
Springer Science and Business Media LLC
Published
2021-01-06
Volume
19
Issue
1
Pages
9-9
ISSN
1479-5876 (ISSN-L)
DOI
10.1186/s12967-020-02667-4
PMC
PMC7788724
OpenAlex
W3120650952
Cited by
119
References
467
Citations by year
2026: 21 · 2025: 17 · 2024: 23 · 2023: 22 · 2022: 23 · 2021: 13
FWCI
2.45
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Translational Medicine (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
Keywords
tumor hypoxia, immune exclusion, solid tumors, tumor microenvironment, cancer immunotherapy, T cell distribution, chromatin remodeling, gene transcription, hypoxia imaging
MeSH terms
Hypoxia, Humans, Immunotherapy, Neoplasms, T-Lymphocytes, Cell Hypoxia, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review